BioCryst Pharmaceuticals Inc (BCRX)

Price$8.57

Value ScoreB

Growth ScoreB

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)10.81%

Price vs S&P 500 (4W)-8.02%

VGM Score67.21

Market Capitalization$2.26B

P/E Ratio (Annual)8.58x

All Metrics

P/CF (Annual)6.52x

Book Value / Share (Quarterly)$0.19

P/TBV (Annual)15.62x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)47.83%

Cash Flow / Share (Quarterly)$1.22

Price vs S&P 500 (YTD)3.30%

Gross Margin (TTM)97.76%

Net Profit Margin (TTM)-51.71%

EPS (TTM)$-1.78

10-Day Avg Trading Volume4.02M

EPS Excl Extra (TTM)$-1.78

Revenue Growth (5Y)117.92%

EPS (Annual)$1.21

ROI (Annual)-92.13%

Gross Margin (Annual)97.82%

Net Profit Margin (5Y Avg)-53.26%

Cash / Share (Quarterly)$0.94

P/E Basic Excl Extra (TTM)8.33x

Revenue Growth QoQ (YoY)7.48%

P/E Normalized (Annual)8.58x

ROA (Last FY)51.32%

Revenue Growth TTM (YoY)75.92%

EBITD / Share (TTM)$-1.76

ROE (5Y Avg)-820.53%

Operating Margin (TTM)-45.07%

Cash Flow / Share (Annual)$1.62

P/B Ratio67.40x

P/B Ratio (Quarterly)18.05x

Net Income / Employee (Annual)$606,600

EV / Revenue (TTM)3.32x

Net Interest Coverage (TTM)4.91x

ROA (TTM)-97.30%

EV / EBITDA (TTM)9.04x

EPS Incl Extra (Annual)$1.21

Current Ratio (Annual)2.06x

Quick Ratio (Quarterly)1.78x

3-Month Avg Trading Volume5.08M

52-Week Price Return-18.11%

EV / Free Cash Flow (Annual)8.52x

P/E Incl Extra (TTM)8.33x

Revenue / Employee (TTM)$2,036,100

Tangible BV / Share (Quarterly)$1.73

P/S Ratio (Annual)2.59x

Asset Turnover (Annual)1.70x

52-Week High$11.31

Operating Margin (5Y Avg)-27.19%

EPS Excl Extra (Annual)$1.21

CapEx CAGR (5Y)37.07%

Tangible BV CAGR (5Y)-18.04%

26-Week Price Return26.74%

Quick Ratio (Annual)1.95x

13-Week Price Return12.78%

Total Debt / Equity (Annual)2.09x

Current Ratio (Quarterly)1.91x

Enterprise Value$2.94B

Revenue / Share Growth (5Y)106.57%

Asset Turnover (TTM)1.88x

Book Value / Share Growth (5Y)-25.06%

Revenue / Employee (Annual)$2,011,100

Inventory Turnover (Annual)2.83x

Pretax Margin (Annual)30.56%

Cash / Share (Annual)$1.29

3-Month Return Std Dev56.46%

Gross Margin (5Y Avg)97.31%

Net Income / Employee (TTM)$-1,052,800

ROE (Last FY)-284.33%

Net Interest Coverage (Annual)-5.92x

EPS Basic Excl Extra (Annual)$1.21

P/FCF (TTM)6.08x

Receivables Turnover (TTM)8.74x

EV / Free Cash Flow (TTM)9.47x

Total Debt / Equity (Quarterly)2.26x

EPS Incl Extra (TTM)$-1.78

Receivables Turnover (Annual)9.41x

ROI (TTM)-106.66%

P/S Ratio (TTM)2.56x

Pretax Margin (5Y Avg)-52.58%

Revenue / Share (Annual)$4.00

Tangible BV / Share (Annual)$0.72

Forward P/E23.66x

Price vs S&P 500 (52W)-46.31%

P/E Ratio (TTM)8.33x

Year-to-Date Return14.23%

5-Day Price Return7.48%

EPS Normalized (Annual)$1.21

ROA (5Y Avg)-17.37%

Net Profit Margin (Annual)30.16%

Month-to-Date Return-2.73%

Cash Flow / Share (TTM)$-1.24

EBITD / Share (Annual)$1.49

Operating Margin (Annual)37.00%

LT Debt / Equity (Annual)1.08x

P/CF (TTM)7.23x

ROI (5Y Avg)-77.15%

P/E Excl Extra (TTM)8.33x

LT Debt / Equity (Quarterly)0.80x

EPS Basic Excl Extra (TTM)$-1.78

P/TBV (Quarterly)4.30x

P/B Ratio (Annual)13.88x

Inventory Turnover (TTM)3.09x

Pretax Margin (TTM)-51.28%

Book Value / Share (Annual)$0.25

Price vs S&P 500 (13W)3.04%

Beta0.59x

P/FCF (Annual)6.57x

Revenue / Share (TTM)$3.66

ROE (TTM)-328.82%

52-Week Low$6.00

vGradeB

gGradeB

mGradeB

vgmGradeB

Show chart for

Earnings Surprise History

Q1 26-0.09est. 0.05

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.27

4.25

Industry Peers — Biological Products(178)

Symbol	Value Score	Growth Score	Momentum Score	Price
BCRXBioCryst Pharmaceuticals Inc	B	B	B	$8.57
AMGNAmgen Inc	C	C	C	$329.13
GILDGilead Sciences Inc	C	B	C	$131.10
ARGXargenx SE American Depositary Shares	D	A	C	$836.09
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$163.68
BIIBBiogen Inc. Common Stock	B	D	B	$192.23
BNTXBioNTech SE American Depositary Share	C	C	C	$91.70
MRNAModerna, Inc. Common Stock	C	B	B	$46.06
NBIXNeurocrine Biosciences Inc	C	B	B	$161.00
EXELExelixis Inc	C	B	B	$50.28
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$298.10

About

BioCryst Pharmaceuticals is a biotechnology company developing small-molecule drugs that target key enzymes involved in infectious and inflammatory diseases. The company's clinical and preclinical pipeline addresses acute and seasonal influenza, hereditary angioedema, filoviruses including Ebola and Marburg, and oncology. BioCryst leverages computational biology and medicinal chemistry to advance its targeted therapeutic candidates.